Abhimanyu Garg is an Endocrinology/Metabolic physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5323 Harry Hines Blvd
Dallas, TX 753907208
Telephone
214-645-0624Provider last certified this registry record 24 May 2021.
Clinical trials
- Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia
Sponsor: University of Texas Southwestern Medical Center
- Orlistat for the Treatment of Type I Hyperlipoproteinemia
Sponsor: University of Texas Southwestern Medical Center
- Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Sponsor: Abhimanyu Garg
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20251 payment
- Chiesi USA, Inc.Program year20241 payment
- Amryt Pharma Holdings LtdProgram year20234 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
79.6%PCSK9 Inhibitor27%Praluent Pen60%Repatha Sureclick40%Part D<11 patientsStatin23.2%Rosuvastatin Calcium39%Atorvastatin Calcium35%Pravastatin Sodium27%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
10.4%SGLT2 inhibitor5.2%Jardiance100%Part D<11 patientsLeptin Analog5.2%Myalept100%Part D<11 patientsHormonal (systemic)
10%l-Thyroxine10%Levothyroxine Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
12 NIH research awards on record, funded 1995–2025 per NIH RePORTER. The latest:
- Genetic and Metabolic Basis of Familial Lipodystrophies
Ut Southwestern Medical Center
FY2025$694,902R01DK105448 - Long term efficacy and safety of orlistat for type 1 hyperlipoproteinemia: a randomized, double-blind, placebo-controlled trial
Ut Southwestern Medical Center
FY2025$436,509R33HL166373
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”